Sodium Oxybate/Potassium Oxybate/Calcium Oxybate/Magnesium Oxybate

Tier C — Watch / trade

Jazz Pharmaceuticals Plc

Originator

2020

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：GABABR

Brand：Xywav

Indications (approved)：猝倒症, 发作性睡病, 嗜睡

Regional status

Approved

2020-07-21

Phase II

2025-03-27

China

Japan

Factories producing this API14

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

14 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Sodium Oxybate/Potassium Oxybate/Calcium Oxybate/Magnesium Oxybate?

Approved indications include: 猝倒症, 发作性睡病, 嗜睡.

When does the Sodium Oxybate/Potassium Oxybate/Calcium Oxybate/Magnesium Oxybate patent expire?

No public expiry year is available for Sodium Oxybate/Potassium Oxybate/Calcium Oxybate/Magnesium Oxybate yet; this page updates once verified.

How do I get a quote for Sodium Oxybate/Potassium Oxybate/Calcium Oxybate/Magnesium Oxybate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27